Related Experiment Video

Updated: Feb 6, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

MEK inhibitors for the treatment of NRAS mutant melanoma

Saro Sarkisian1, Diwakar Davar2

  • 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Drug Design, Development and Therapy
|August 30, 2018
PubMed

Insights

Melanoma incidence is rising, with new treatments like PD-1/CTLA-4 and MAPK pathway inhibitors improving survival. This review focuses on binimetinib, a novel MEK inhibitor, for NRAS-mutant melanoma.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Melanoma incidence and prevalence are rapidly increasing globally.
  • Treatment landscape has evolved from interleukin 2 and T-cell therapy to immune checkpoint inhibitors (PD-1, CTLA-4) and targeted small molecule inhibitors.
  • Mitogen-activated protein kinase (MAPK) pathway inhibitors, including BRAF/MEK inhibitors, have shown significant survival benefits.

Purpose of the Study:

  • To review the preclinical data and clinical development of binimetinib, a novel MEK inhibitor.
  • To explore the potential therapeutic role of binimetinib in NRAS-mutant melanoma.

Main Methods:

  • Review of preclinical studies on binimetinib.
  • Analysis of clinical trial data for binimetinib.
  • Discussion of MEK inhibition in the context of melanoma signaling pathways.

Main Results:

  • Binimetinib demonstrates promise as a targeted therapy.
  • MEK inhibitors, including binimetinib, offer improved survival outcomes in melanoma.
  • NRAS-mutant melanoma represents a key area for MEK inhibitor application.

Conclusions:

  • Novel MEK inhibitors like binimetinib represent a significant advancement in melanoma treatment.
  • Binimetinib holds potential for improving outcomes in patients with NRAS-mutant melanoma.
  • Further clinical development is warranted to establish the full efficacy of binimetinib.
Keywords:
BRAFERKMAPKMEKNRASadvancedbinimetinibmelanomametastatic

More Related Videos

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

7.1K
A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

13.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
613
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
544
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
679
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K